High intra-tumour diversity increases the likelihood of disease progression 2 as different subclones respond differently to microenvironmental cues. Treatment of heterogeneous tumours favours the selection of resistant subclones, leading to therapeutic failure. Heterogeneous tumours also display phenotypes different from those of individual clones; thus, intra-tumour heterogeneity has a significant impact on tumour progression and therapeutic resistance.
T umours are mixtures of cells with distinct characteristics 1 . High intra-tumour diversity increases the likelihood of disease progression 2 as different subclones respond differently to microenvironmental cues. Treatment of heterogeneous tumours favours the selection of resistant subclones, leading to therapeutic failure. Heterogeneous tumours also display phenotypes different from those of individual clones; thus, intra-tumour heterogeneity has a significant impact on tumour progression and therapeutic resistance.
Metastatic disease is responsible for most cancer-associated mortality; therefore, understanding the drivers of metastatic progression is key for improving clinical outcomes. Cancer genome sequencing studies have identified limited genetic differences between primary and metastatic tumours and demonstrated extensive subclonal heterogeneity in both primary and distant lesions 3, 4 . However, the mechanism(s) by which polyclonal primary tumours produce polyclonal metastases remains elusive. Moreover, several recent studies implicated microenvironmental changes as key mediators of metastatic dissemination and outgrowth 5, 6 , thus highlighting the role of non-cell-autonomous factors in tumour evolution.
Clonal cooperation drives polyclonal metastasis
We have been investigating the effect of subclonal interactions on tumour phenotypes using a human breast cancer cell line (MDA-MB-468)-derived xenograft model of intra-tumour heterogeneity. We previously established that a minor subclone can drive tumour growth through non-cell-autonomous interactions, supporting long-term subclonal heterogeneity Articles NAtuRE CELL BIOLOGy also known as VEGFD) was largely able to reproduce this phenotype. Omission of IL11 + cells from polyclonal tumours decreased tumour growth, suggesting that IL11 and FIGF may cooperate. In addition, both polyclonal tumours and tumours comprised of only IL11 and FIGF subclones were highly metastatic, but the underlying mechanism remained undefined.
To dissect the molecular basis of this metastasis-driving subclonal cooperation, we first investigated the clonality of metastases of primary MDA-MB-468 tumours comprising IL11
+ and FIGF + driver subclones, as well as neutral subclones. Monoclonal or polyclonal mixtures of green fluorescent protein (GFP) and luciferase-expressing parental cells, red fluorescent protein (RFP) and V5-tagged IL11
+ cells, and RFP + FIGF + cells were implanted into the mammary fat pads of immunodeficient NOG mice. We monitored the primary-tumour growth by weekly caliper measurements and macrometastatic lesions by weekly bioluminescence imaging. Polyclonal tumours initiated from 5% IL11
+ and 5% FIGF + RFP + cells with 90% GFP + parental cells grew faster and were more metastatic than monoclonal and parental tumours (Fig. 1a-c and Supplementary Table 1) . Immunohistochemistry-based quantification of human cytokeratin + (CK + ) cells in the lungs revealed an increased number of metastatic lesions in mice with FIGF + primary tumours (Fig. 1d ,e) despite small primary tumours. However, most of these were micrometastases, which could only be detected as single cells by immunohistochemistry, whereas the lungs of mice with polyclonal primary tumours were filled with macrometastases emitting high bioluminescence signals (Fig. 1b) . The increased metastases by polyclonal tumours were not simply due to their faster growth, as this trend was still observed when primary tumours were surgically removed when they reached a diameter of 1 cm ( Supplementary Fig. 1a,b) . Furthermore, IL11 + monoclonal tumours grew faster than parental and neutral clones but were not as metastatic as polyclonal tumours. Thus, macrometastatic outgrowth is a phenotype unique to polyclonal tumours. Immunofluorescence demonstrated that metastases of polyclonal tumours were also mostly polyclonal, composed of V5-tag + IL11 and FIGF driver and GFP + parental subclones, the latter of which did not produce significant macrometastases on their own except for rare GFP + monoclonal metastases (Fig. 1f,g ). These results show that polyclonal tumours behave differently from monoclonal tumours and that IL11 + and FIGF + subclones driving tumour growth and dissemination, respectively, cooperate to generate frequent large polyclonal metastases. This cooperation is likely to be indirect, as close cell contact between driver and neutral subclones was not commonly observed and clonal distribution within metastatic lesions was random (Fig. 1g,h ).
indirect clonal cooperation via the microenvironment
To explore the mechanisms by which driver subclones cooperate to promote metastasis, we generated polyclonal tumours composed of fluorescently labelled driver clones (10% FIGF-mCherry and 10% IL11-GFP cells) and neutral clones (40% Thy1.1 cell surface marker and 40% cyan fluorescent protein(CFP)-expressing cells). To ensure that a sufficient number of cells of each fraction could be sorted from these tumours, 10% driver clones were used in this experiment. As controls, we established tumours with 100% of each individual clone. The mice were killed when the primary tumours reached approximately 2 cm. The primary and metastatic lesions were dissociated, and fluorescently labelled cancer and unlabelled murine cells were purified by fluorescence-activated cell sorting (FACS) and analysed by RNA sequencing (RNA-seq; Fig. 2a , Supplementary Fig. 1c and Supplementary Table 2) .
We first investigated whether a common transcriptional program was induced by the driver subclones in polyclonal tumours. We compared the expression profiles of each subclone purified from polyclonal tumours with that of the parental tumours (Supplementary Table 3 ). We found 36 commonly upregulated genes in the fractions from tumours with driver clones (Fig. 2b) , including TMEM173, which encodes STING-an immune modulator 8 -and several extracellular matrix components. These expression changes suggested that the driver subclones may promote metastasis by altering the tumour microenvironment. We therefore analysed the differences in stromal cells (that is, cells lacking human cancer cell markers) from monoclonal and polyclonal primary tumours, and lungs. Given that the parental cells did not generate metastases, we used lung tissue from mice with 100% parental cell tumours as controls in our comparisons. Principal component analyses (PCA) demonstrated a trend towards clustering according to the tumour of origin, implying that tumour cells have a significant impact on the stromal gene expression ( Supplementary Fig. 2a,b and Fig. 2c,d) . Using MetaCore 9 , we analysed the pathway and process-network enrichment within the upregulated genes in the stromal cells of primary tumours capable of seeding metastases (that is, containing a driver subclone) compared with the stroma of parental tumours (Supplementary Tables 3 and 4) . Interestingly, nine of the ten top significantly enriched pathways were immune related ( Fig. 2e and Supplementary Fig. 2c ). In contrast, all ten top pathways enriched in non-cancer cells from the lungs of mice with polyclonal tumours were related to vesicular transport and cell motility (Fig. 2e) . Comparisons of the FIGF and IL11 fractions of polyclonal tumours with 100% FIGF + or IL11 + tumours also showed upregulation of angiogenesis-related genes (Supplementary Table 3 ). Immunohistochemistry analysis of CD31 blood and LYVE1 lymphatic vessel markers confirmed this upregulation even in primary tumours ( Supplementary Fig. 2d ).
We also analysed the relative frequencies of each of the four subclones within polyclonal tumours by FACS and found that the IL11 + and FIGF + subclones remained as minor fractions ( Supplementary  Fig. 2e ). Thus, their ability to drive tumour growth and metastasis did not require clonal expansion, indicating a non-cell-autonomous mechanism. Therefore, subclonal cooperation in primary tumours promotes metastasis by modulating the microenvironment of the primary and metastatic lesions.
Polyclonal tumours affect leukocytes
To follow up on our finding of immune-related changes in the stroma of metastatic-capable primary tumours and to analyse leukocytes, we repeated the polyclonal and monoclonal xenograft experiment using luciferase-expressing cells to monitor metastases. Immunodeficient NOG mice retained innate immune and myeloid cells (albeit not fully functional), and the myeloid-related pathways were highly upregulated in the primary tumours driving metastases. We assessed the qualitative changes in blood leukocytes by FACS at three weeks after tumour initiation and at the six-week experimental endpoint when the primary tumours, lungs and bone marrow were also collected ( Fig. 3a and Supplementary  Fig. 3a) . The most significant differences were detected in neutrophils and monocytes ( Fig. 3b and Supplementary Fig. 3b ). The relative fraction of neutrophils was significantly higher in the blood, primary tumours and lungs of mice with polyclonal and IL11
+ monoclonal tumours, compared with mice bearing parental cell tumours, whereas the fraction of CD11c
+ cells was significantly lower in the blood and lungs, macrophages showed a slight decrease in primary tumours and lungs, and monocytes were decreased in the blood and primary tumours ( Fig. 3b and Supplementary Fig. 3b ).
Neutrophil influx has been associated with IL11 signalling and inflammatory bursts 10 ; we therefore analysed CD45
+ bone marrow cells for IL11RA expression. Approximately 20-30% of the CD45 + cells of the mice bearing IL11 + or FIGF + monoclonal and polyclonal tumours were IL11RA + (Fig. 3c) , and the fraction was (Fig. 3d) . Hence, the presence of minor metastasis-promoting subclones within tumours alters the immune system, particularly the neutrophil population.
In breast cancer patients, distant metastases are usually recurrences after the surgical removal of primary tumours and some studies have suggested that the surgery itself may induce metastatic lesions 11, 12 . Thus, we performed mock or primary-tumourremoval surgery in another experiment but did not observe any effects of surgery on the metastatic burden in the lungs ( Supplementary Fig. 4a-c) . Therefore, surgery-related wound healing and inflammation are not inherently responsible for the observed immune-related changes or increased metastasis in our polyclonal tumours.
iL11-FiGF cooperation drives pro-metastatic systemic changes
Next, we investigated whether the metastasis-promoting subclones exert their effects via local or systemic changes. We injected a 1:1 mixture of MDA-MB-468 cells expressing doxycycline (DOX)-inducible, haemagglutinin (HA)-tagged IL11 and FIGF into the right mammary fat pad and a slow-growing, non-metastatic patient-derived xenograft (PE1) into the contralateral mammary fat pad. The mice were randomized into −/+ DOX groups to induce IL11 and FIGF expression. As expected, the IL11 +
FIGF
+ tumours grew faster than parental tumours, although the difference was not as profound as in polyclonal tumours with constitutive expression. The growth of the PE1 primary tumours was not affected by the contralateral IL11 +
+ tumour (Fig. 4a,b) , but lung metastases were significantly increased in the +DOX mice (Fig. 4c,d ). Using . n = 3 independent tumours per group. e, MetaCore GO Processes overrepresented in the expression profiles of the stroma of primary tumours (n = 3) and metastasis-bearing lung cells (n = 3). The colour scale corresponds to −log P value of the significance of enrichment, which was calculated using the MetaCore enrichment analysis test.
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NAtuRE CELL BIOLOGy immunohistochemistry for the HA tag, we found that the metastatic lesions were a mixture of HA + and HA − cells, with the latter presumably representing the PE1 cells (Fig. 4c ). To confirm that these negative cells were not MDA-MB-468 cells that had lost the expression of HA-tagged IL11 and FIGF, we performed fluorescence in situ hybridization (FISH) to the epidermal growth factor receptor (EGFR) and the human-specific CEP8, as MDA-MB-468 cells have an EGFR amplification that is not detected in PE1, whereas CEP8 marks all human cells. This analysis clearly demonstrated that metastases were a mixture of PE1 and EGFR amp IL11 (Fig. 4e ). Single-cell quantification of the FISH signal showed a significant correlation between the numbers of IL11
) and PE1 (CEP8 only ) cells, implying potential local interactions between these populations (Fig. 4f) . Therefore, IL11 and FIGF promote metastasis via systemic effects, potentially mediated by neutrophils.
Depletion of neutrophils affects metastases
We treated mice with a neutrophil-depleting Ly6G antibody 13 to determine whether neutrophils are required for the increased metastasis driven by IL11 and FIGF. To determine the optimal timing to initiate treatment, we used mathematical modelling to predict the onset of metastasis based on our bioluminescence data (see Methods for details). Our computational framework considers two types of cells-those residing in the primary tumour and those that have left the primary site ( Supplementary Fig. 4d ). Each time a cell leaves (at a metastatic rate q), it establishes a new metastatic colony. Growth and dissemination rates were estimated from experimental data ( Supplementary Fig. 4b ) dependent on the experimental condition ( Supplementary Fig. 4e ). Briefly, to estimate the metastatic rate q, we minimized the distance between the experimental results and model predictions for the distribution of the size of the first metastasis six weeks after the start of the experiment and the primarytumour size when the first metastasis was detected. We identified the metastatic rate as 10 −7 < q < 10 −6 per cell per week and, using this, defined the timing of the first metastatic cell leaving the primary site as 5.18 ± 2.45 d for IL11
+ monoclonal tumours and 5.11 ± 2.45 d for polyclonal tumours when q = 10
, and 1.33 ± 1.05 and 1.68 ± 0.91 d, respectively, when q = 10 −6 (Supplementary Fig. 4f -k). Thus, we concluded that treatment should be initiated immediately after tumour inoculation to prevent metastatic seeding.
We initiated polyclonal xenografts with 10% DOX-inducible IL11 + and FIGF + , and 90% parental cells and assigned animals to receive DOX with a neutrophil-blocking anti-Ly6G antibody or an isotype control, which was administered for four weeks ( Supplementary Fig. 5a ). We confirmed the efficacy of the antiLy6G antibody treatment after two weeks by assessing the blood neutrophil counts ( Supplementary Fig. 5b-d) . At six weeks, we Table 1 for the raw data. The box-and-whisker plots in all bar graphs show the mean (midline), and 25th-75th (box) and 5th-95th (whiskers) percentiles. P values were calculated using an unpaired two-tailed Student's t-test.
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NAtuRE CELL BIOLOGy found that neutrophil depletion did not affect the growth of the primary tumour (Fig. 4g,h ) but significantly decreased the proportion of CK + metastatic cells in the lungs of mice compared with mice treated with the isotype control (Fig. 4i,j) . The comparison to untreated animals achieved borderline significance. Unexpectedly, anti-Ly6G treatment increased the metastatic load in −DOX mice with tumours that did not express IL11 and FIGF (Fig. 4i,j) . These results demonstrate that the systemic depletion of neutrophils On average, 2,900 cells per field and three fields per sample were counted. For each group, the lungs of five mice were analysed. Data shown are representative of two independent experiments. The box-and-whisker plots show the mean (midline), 25th-75th (box) and 5th-95th (whiskers) percentiles, and outliers (dots). The two-tailed unpaired Student's t-test P value is shown. e, Representative images of EGFR and CEP8 FISH on primary tumour and lung metastasis under DOX treatment. Scale bars, 25 μm. Staining was repeated twice with similar results. f, Correlation between the numbers of cells per metastatic lesion that are EGFR amp or have CEP8 only FISH signal. Three or four fields of view of the lungs from four animals were quantified; a total of 16 lesions were analysed. The Pearson's correlation R 2 and two-tailed Student's t-test P values are indicated. g-j, Neutrophil depletion in mice bearing polyclonal tumours with minor driver subclones. g,h, Tumour growth kinetics (g) and final tumour weight (h; n = 5 per group). The dashed line in g marks the anti-Ly6G and isotype-antibody treatment duration. Data are shown as the mean ± s.d. i, Representative images of CK staining of the lungs of the treated mice. Scale bars, 100 μm. j, Quantification of CK + cells. On average, 2,600 cells per field and three fields per sample were counted. For each group, the lungs of five mice were analysed. The box-and-whisker plots show the mean (midline), 25th-75th (box), and 5th-95th (whiskers) percentiles, and outliers (dots). + cells from the blood, primary tumours and lungs of the mice by FACS six weeks after tumour inoculation, and performed single-cell RNA-seq (scRNAseq) 13 . Clustering analysis revealed a minor fraction of contaminating CK + EGFR + cancer cells, that were removed from subsequent analyses ( Supplementary Fig. 6a-c) , as well as numerous identifiable leukocyte subpopulations (Fig. 5a, Supplementary Fig. 6d-g and Supplementary Table 5 ). CD45
+ cells from the lungs, blood and primary tumours differed in their contribution to the distinct cell clusters (Fig. 5b) . For example, M1 macrophages were found only in primary tumours, whereas M2 macrophages were present only in lung metastases. Given that our previous results indicated that neutrophils contribute to metastasis, we compared the single-cell transcriptomic profiles of blood and lung neutrophils from mice with or without DOX treatment. The IL11-and FIGF-induced upregulation of several pathways-including TGFβ and JAK-STAT signalling-associated with pro-tumorigenic and pro-metastatic immune signatures in neutrophils from the lungs but not from blood ( Fig. 5c and Supplementary Tables 6,7) . Despite the observed change in lung neutrophils, we did not detect IL11-or FIGF-receptor expression in this cell population through scRNA-seq. However, cells with IL11RA transcripts were clearly present in a separate cluster (Fig. 5d) , which could not be classified as either neutrophils or any other leukocyte subpopulation. These IL11RA + cells express IL6ST, which encodes GP130, a coreceptor necessary for IL11 signalling, and STAT3, a downstream IL11 effector (Supplementary Fig. 6f ). Based on gene expression in this cluster (Supplementary Table 8 ), which also included extracellular-matrix and development-related proteins, we denoted this population as IL11-responsive mesenchymal stromal cells (MStrCs). Although this population does not express the classic mesenchymal stem cell (MSC) markers, its signature is rich in stem-cell-related genes, implying that it could be a previously uncharacterized MSC-like cell type. Previous studies have described interactions between MSCs and leukocytes mediated by various cytokines and chemokines 14 . Thus, we identified secreted factors from our MStrC-specific expression signatures using gene-enrichment analysis and analysed them in different conditions (Fig. 5e) . Comparison of lung MStrCs from −/+ DOX animals revealed that the induction of IL11/FIGF expression in the primary tumours upregulated the expression of chemoattractants for pro-metastatic neutrophils including CXCL12, CXCL14 and CXCL1 (Fig. 5e) .
We performed immunofluorescence and FACS to validate the presence of CD45 + IL11RA + cells in the lungs of mice and to assess co-expression of MStrC markers with IL11RA . CD45 +
IL11RA
+ cells were relatively common in the spleen and present as a rare subpopulation with mesenchymal morphology in the lungs (Fig. 5f ). Rare IL11RA high cells co-expressing PLXDC2 and ANTRXR1-markers of these cells based on scRNA-seq (Supplementary Table 8 )-representing 0.5-1% of cells were also identified in the lungs of mice by FACS ( Fig. 5g and Supplementary Fig. 6h-l) . Immunofluorescence analysis of the mice lungs demonstrated the presence of rare IL11RA +
PLXDC2
+ cells with mesenchymal morphology (Fig. 5h) . Lastly, we sorted cells from the lungs of mice with IL11 + /FIGF + tumours by IL11RA expression and analysed their gene expression profiles. Our MStrC signature was significantly enriched in IL11RA high samples (Fig. 5i) , and enrichment for cell adhesion and extracellular-matrix remodelling-related process networks was noted (Supplementary Table 9 ).
In summary, our scRNA-seq data and its subsequent validation by FACS, immunofluorescence and bulk RNA-seq, uncovered an interaction loop among different subpopulations of bone-marrowderived cells that mediates the pro-metastatic effects of tumour cellsecreted IL11 and FIGF (Fig. 5j) . The expression of IL11 and FIGF in a minor subpopulation of cancer cells in polyclonal tumours alters these MStrCs in the lungs, leading to the activation of 'effector' neutrophils that are crucial for metastatic progression.
iL11-driven signatures in human metastatic breast cancer
To investigate the clinical relevance of our findings, we analysed the expression of IL11 and IL11-driven neutrophil and MStrC signatures in breast cancer metastases. IL11 is amplified in a subset of primary breast tumours and this amplification is more commonly observed in metastases (cBioPortal 15, 16 ; Fig. 6a ). Based on our data, IL11 and FIGF can drive significant systemic changes even when expressed by minor subclones, which makes them difficult to detect. We thus explored whether gene signatures of IL11/FIGF-activated neutrophils and MStrCs, defined by our single-cell RNA data, are present in distant metastases in the Metastatic Breast Cancer Project (MBCP) dataset 17 , which contains RNA expression data of 156 distant metastatic lesions. As most of the systemic changes were IL11-driven in our experimental system, we classified metastatic lesions into IL11 high and IL11 low groups based on the messenger RNA levels. We then compared the IL11 high and IL11 low metastases for the expression of gene signatures activated by IL11/FIGF in the lung and blood neutrophils and in MStrCs (Supplementary Table 6 ). The signatures for the activated lung and blood neutrophils, and lung MStrCs were significantly higher in IL11 high than in IL11 low metastases (Fig. 6b) . In contrast, the gene signature of IL11/FIGF-activated cancer cells, derived from genes expressed by neutral clones in polyclonal tumours, did not correlate with IL11 expression in metastases (Fig. 6b, bottom panel) . Analysis of the expression of these gene signatures in matched primary and metastatic lesions using the MBCP dataset showed that activated neutrophil and MStrC signatures were significantly higher in metastases, whereas cancer cell signatures did not show a difference (Fig. 6c, left) . To eliminate potential bias due to differences in tissue type used for RNA extraction (formalin-fixed paraffin-embedded for primary tumours and frozen for metastases), we also compared the MBCP metastases to ER + tumours in the The Cancer Genome Atlas (TCGA) dataset with essentially the same findings (Fig. 6c, right) . Therefore, IL11/FIGFdriven microenvironmental changes are also detected in human breast cancer patients and are associated with distant metastases.
Discussion
Polyclonal metastasis of breast cancer has been described in several recent studies 18, 19 . Here we provide evidence that minor subpopulations in polyclonal tumours can drive metastatic progression and outgrowth of polyclonal metastases that also contain neutral subclones (non-metastatic on their own) by modulating the local and systemic microenvironments.
In our study, we focused on two secreted factors, selected based on our previous data 7 , which are expressed by minor subclones that cooperate to drive metastasis. IL11 belongs to the IL6 family of cytokines and has been shown to play a role in progression and resistance of multiple cancer types, including prostate and colon cancer 20, 21 . In breast cancer, IL11 has been implicated in therapeutic resistance 22 and bone metastasis 23 , as well as a marker of poor outcomes 24 . FIGF is a ligand for VEGFR2 and VEGFR3, and can stimulate both angiogenesis and lymphangiogenesis 25, 26 . 
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NAtuRE CELL BIOLOGy macrometastatic outgrowths. In our model, IL11 and FIGF secreted by minor subclones have profound effects on the metastatic ability of breast cancer cells. Although IL11 acts on leukocytes to induce metastasis-permissive changes in the microenvironment of distant organs, FIGF acts more locally by increasing lymphangiogenesis and vascular permeability. However, because these subclones represent only 1-5% of the tumour cells, their presence and their secreted factors may be difficult to detect in clinical samples, making it challenging to predict their metastasis-promoting effects in human tumours. Nevertheless, our analysis of human metastatic breast tumours suggests that the systemic changes in immune and other bone-marrow-derived cells, which are induced by even low levels of these secreted factors, can be detected and potentially exploited for patient stratification and treatment.
We identified neutrophils as the leukocyte population required for IL11-and FIGF-induced polyclonal metastasis. A caveat of our approach is the use of immunocompromised animals, which did not allow us to study the roles of lymphoid cells in metastatic cooperation. Thus, it is possible that other immune cells may also play a role in the metastatic process. Neutrophils have been implicated in metastatic progression by promoting the pre-metastatic niche [27] [28] [29] [30] [31] . Furthermore, a high pre-operative neutrophil-to-lymphocyte ratio is associated with poor prognosis in breast cancer patients 32 
.
Neutrophils have also been shown to have anti-tumour effects and to inhibit seeding of cancer cells in the lungs 33, 34 . In our experiments, depending on whether or not the tumours expressed IL11 and FIGF, the depletion of neutrophils could either decrease or enhance lung metastasis. These seemingly contradictory roles for neutrophils could potentially be explained by our observation, based on scRNA-seq data, that there are several different types of neutrophils, potentially pro-and anti-tumorigenic, depending on the anatomical location and gene expression patterns. Our findings are therefore in agreement with reports that the context and temporal infiltration of monocytes and neutrophils is critical to outcome 31, 35, 36 , and that heterogeneity of not only tumour cells but also immune cells must be considered. Another point to consider is that the injection of isotype-control antibody unexpectedly increased the metastatic burden, potentially by triggering an inflammatory response. The magnitude of the neutrophil-depletion effect on metastasis may therefore be very sensitive to the systemic environment of the host.
The use of single-cell expression profiling of CD45 + cells in our study allowed us to uncover interactions between different subpopulations. We found that leukocytes may not be the direct cellular targets of IL11, but may be indirectly affected through factors secreted by MStrCs responsive to IL11. Interestingly, these cells also express PLXDC2 and ANTXR1, which are highly expressed in tumour-associated endothelial cells 37, 38 . Thus, these IL11RA + mesenchymal cells may represent progenitors that can give rise to multiple cell types. Further characterization of these cells and their effector leukocytes will shed new light on the biology of pro-tumorigenic neutrophils. Table 1 for the raw data.
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An improved understanding of neutrophil subtypes and the development of tools to target pro-metastatic neutrophils, in combination with cancer cell-targeting drugs, could potentially be used to prevent breast cancer metastasis.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41556-019-0346-x.
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Methods
Cell lines and tissue culture conditions. The parental MDA-MB-468 cell line was used to generate IL11-and FIGF-overexpressing subpopulations using lentiviral vectors as previously described 7 . Inducible IL11 and FIGF expression was achieved by cloning the respective complementary DNA into pLentiX2 vectors, followed by viral transduction of the respective constructs into parental MDA-MB-468 cells 7 and selection with 2 μg ml −1 puromycin. All cell lines were cultured in McCoy's medium (Cell Grow) with 10% fetal bovine serum (FBS; HyClone) and 10 μg ml −1 insulin (Life Technologies) at 37 °C with 4% CO 2 . Cell-line identity was confirmed by short-tandem-repeat analysis and the cells were regularly tested for mycoplasma (Venor GeM mycoplasma detection kit, Sigma).
PE1 was a primary cell line from the pleural effusion of a patient with triplenegative (ER − PR − HER2 − ) breast cancer. The pleural effusion was collected under the Dana-Farber Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB) protocol no. 93-085 following written informed consent and used in the lab in compliance with DF/HCC IRB protocol no. 14-400 approved for the use of de-identified tissue samples. The study is compliant with all of the relevant ethical regulations regarding research involving human participants.
Xenograft experiments. All of the animal procedures were approved by DFCI IACUC and performed according to the DFCI protocol no. 11-023. The study is compliant with all of the relevant ethical regulations regarding animal research. Female NOG (NOD.Cg-Prkdc scid Il2rg tm1Sug /JicTac) mice (Taconic) were used at 4-6 weeks of age. For the tumour growth assays, a total volume of 50 μl containing 3 × 10 6 cells in 50% Matrigel (BD Biosciences) in DMEM media (Gibco) was injected into the mammary fat pad. Tumour growth was measured weekly with a caliper. In some experiments, metastatic growth was followed by weekly bioluminescence imaging measurements of luciferase activity using an IVIS imaging system. The size of the macrometastasis was determined by Living Image software (PerkinElmer) analysis of the areas of bioluminescence in the images. Regions of interest were automatically selected by the software and the area of each individual region of interest was measured. The parental tumour region of interest was excluded from the analysis. Blood samples at early time points were collected via retro-orbital bleeding. For the in vivo inducible expression of IL11 and FIGF, the mice were switched to a DOX diet 24 h after a mammary-fat-pad injection.
FACS analysis.
For all experiments, blood was freshly collected and processed immediately, whereas bone marrow was viably frozen after erythrolysis. Tumour and lung samples were digested to single-cell suspensions with collagenase type IV (Worthington, cat no. LS004189)/DNase I digestion buffer (2 mg ml −1 and 0.02 mg ml −1 , respectively, in DMEM with 10% FBS and 1% Pen-Strep). The digestion was performed at 37 °C with stirring for 1 h for tumour tissues and 0.5 h for lung tissues. The digestion was terminated with DMEM containing 10% FBS, and the cells were washed and stained immediately. The red blood cells were lysed with lysis buffer (BD Pharm Lyse, BD Biosciences). After washing with FACS buffer (2% FBS in PBS and 2 mM EDTA), cells were stained with antibody cocktail 1 or 2 (Supplementary Table 2 ) for 20-30 min on ice and washed twice. The final cell pellet was resuspended in FACS buffer with or without 7AAD for viability detection. The analysis was performed on a BD FACS Canto system (BD Biosciences). Gating and analysis of the peripheral blood mononuclear cell subpopulations were performed using FlowJo software.
In vivo neutrophil depletion. The mice were treated with 12.5 μg anti-Ly6G (BioCell) or isotype-control antibody (BioCell) in a 100 μl volume via intraperitoneal injections 24 h post mammary-fat-pad injection. The treatment was administered daily for 28 d. The on-target effect was measured after two weeks of treatment by FACS analysis of the peripheral blood mononuclear cells in the mouse blood.
Immunofluorescence and immunohistochemistry. After collection, xenograft samples and mouse organs were fixed in buffered formalin overnight and stored in 70% ethanol before being processed into formalin-fixed paraffin-embedded blocks by the DFCI Pathology Core. Staining was performed on 5-μm sections. Before staining, the slides were baked at 65 °C and a standard deparaffinization protocol using xylene and ethanol washes was used. If required, antigen retrieval was performed using citrate buffer (pH 6; Invitrogen) or Target Retrieval solution (pH 9; Dako) for 20 min in a steamer. Some antibodies performed better after a 10-min permeabilization step using 0.5% Triton X-100 (Sigma Aldrich) in PBS. The specific antibodies and dilutions used are listed in Supplementary  Table 2 . Incubation with primary antibodies diluted with PBST buffer (0.05% Tween 20 in PBS) in 5% goat serum was performed overnight at 4 °C. After three washes with PBST, the secondary antibody was applied to the slides and incubated for 1 h at room temperature. For immunohistochemical analysis, the ABC peroxidase system (Vectastain, ABC System Vector Laboratories) was used with 3,3′-diaminobenzidine as the colorimetric substrate. Counterstaining was performed using Harris haematoxylin and Scott's tap water substitute (Leica). Automated quantification of individual positive cells was performed using ImageJ macros (available on request) by scoring the total cell numbers based on nuclear staining and strongly positive cells across five different areas of a given specimen.
Following immunofluorescent staining, the slides were counterstained with DAPI (Vectashield Hard Set Mounting Medium with DAPI) and stored for at least 24 h at −20 °C to reduce autofluorescence. Images from multiple areas of each sample were acquired using a Nikon Ti microscope attached to a Yokogawa spinning-disk confocal unit using a 603 plain apo objective and an OrcaER camera controlled by Andor iQ software or with a Leica SP5 confocal scanning microscope.
Stroma and epithelial cell fractionation and RNA-seq. Cell fractionation. To separate subpopulations from polyclonal tumours, the following MDA-MB-468 cell line derivatives with fluorescent tags were used: neutral clones (expressing CFP and Thy1.1), and IL11-mCherry and FIGF-GFP clones. Polyclonal tumours were dissociated to a single-cell suspension by digestion in collagenase/hyaluronidase digestion buffer (2 mg ml −1 each in DMEM with 10% FBS and 1% Pen-Strep). After washing with PBS, the samples were resuspended in FACS buffer (2% FBS in PBS) and the populations expressing CFP, mCherry, GFP and Thy1.1 were sorted into FACS buffer, pelleted and stored at −80 °C. The negative cell population was also collected, as this constitutes the tumour stroma. The same procedure was performed on metastatic lungs, except all labelled cells were collected as a group due to their overall small numbers in metastatic lungs.
mRNA extraction and library preparation. Messenger RNA selection and whole transcriptome amplification were performed as previously described with some modifications 39, 40 . A primer 5′-phosphorylated oligo-dT24 (pdT24) was used to select mRNA from total RNA. For denaturation and primer annealing, total RNA was mixed with dNTPs (25 mM) and pdT24, incubated in a PCR machine preheated to 68 °C for 5 min and then immediately placed on ice.
Reverse transcription was performed with the addition of the First-Strand buffer, dithiothreitol, RNase inhibitor and 10 U μl −1 Superscript reverse transcriptase III. Double-stranded cDNA was generated by the addition of 30 μl of a mix containing 10×Second Strand buffer, dNTPs (25 mM), Escherichia coli DNA ligase (10 U μl ), followed by a 3 h incubation at 16 °C and 5 min at 70 °C. The product was purified with the Genomic DNA Clean and Concentrator kit (Zymo Research). Next, DNA blunt-ending, 5′-end phosphorylation and ligation were performed with an End-It DNA end-repair kit (Epicentre) and T4 DNA ligase (Epicentre). The product was directly amplified by adding a mixture of Reaction Buffer and DNA polymerase from the REPLI-g UltraFast kit (Qiagen) at a 15:1 ratio. The amplification reaction was carried out at 30 °C for 2 h. The amplified product was purified using the same Genomic DNA Clean and Concentrator kit (Zymo Research). Typically 5-10 μg of mRNA-derived cDNA amplicons were obtained when eluted in 50 μl elution buffer. The amplicons were then evaluated for quantity, coverage and purity by PCR using a set of primers for housekeeping genes (GAPDH: forward, 5′-GTCTCCTCTGACTTCAACAGCG-3′ and reverse, 5′-ACCACCCTGTTGCTGTAGCCAA-3′; B2M: forward, 5′-CCACTGAAAAAGATGAGTATGCCT-3′ and reverse, 5′-CCAATCCAAATGCGGCATCTTCA-3′), cDNA 5′ ends (CERB5: forward, 5′-GTCAGTGAACTCCAGCATCATGG-3′ and reverse, 5′-GTGGTGAGTCAATGCAGCCTTC-3′) and genomic DNA (10p: forward, 5′-GTTCTGCTGCCTCTACACAGG-3′ and reverse, 5′-ATCCTTCTGTGAACTCTCAAATTC-3′). A Nextera XT DNA sample preparation kit (Illumina) was used according to the manufacturer's recommendations with minor modifications to construct cDNA libraries. Briefly, cDNA amplicons were fragmented and barcoded by tagmentation using Tn5 DNA transposase. The tagmented cDNA was amplified with a limited-cycle PCR program. During the PCR step, indices 1 and 2 were added to enable cluster generation and multiplexed sequencing. The extension time was increased from 30 s to 60 s. The amplified cDNA libraries were purified and cleaned using 0.6×Agencourt AMPure XP (Beckman Coulter) and fresh ethanol, and eluted in TE buffer. The quality of the sequencing libraries was assessed using a highsensitivity DNA chip (Agilent). Finally, the libraries were deep sequenced using a HiSeq2000 sequencer (Illumina).
Clustering based on differentially expressed genes. We analysed the stroma from primary tumours and metastatic lungs separately. First, we normalized for sequencing depth and applied the variance stabilizing transformation, both implemented in DESeq2. The top 1,000 most variable genes were used to cluster the samples based on the expression of these genes (Euclidean distance and complete clustering). The heat map itself depicts relative variance-stabilizingtransformed values across samples (the difference between the value of the sample for a given gene and the mean expression of the given gene across all samples) and hence negative values were obtained. Note that this way of displaying the expression does not affect the sample clustering when compared with clustering based on expression-correlation values.
RNA-seq of lungs.
Lungs from tumour-bearing mice with and without DOX were isolated and dissociated into single-cell suspensions as described above. The lungs from five mice were pooled for each group with two replicates. Staining for IL11R and PLXDC2 was performed as described in the 'FACS analysis' section. 
Code availability
The mathematical modelling code is available from the corresponding author on request.
utilizing two measurement methods were available for the primary site: tumour diameter by caliper measurements and the largest cross-sectional area of a tumour by bioluminescence detection. For the metastatic sites, caliper measurements were not available because the tumour sizes were too small to be measured; therefore, only cross-sectional-area measurements were performed by bioluminescence detection. Based on the idea that growth estimation based on caliper measurements is more accurate than bioluminescence detection methods due to oversaturation of large lesions, we calculated the growth rates of metastatic sites by converting bioluminescence to caliper measurements using primary-site data. Specifically, we calculated the ratio of the estimated growth rates of the primary sites by the two aforementioned measurement methods, caliper measurement and bioluminescence detection, and multiplied it by the growth rates of the metastatic sites estimated by bioluminescence. We converted the tumour volume to cell numbers with the assumption of a spherical shape (10 9 cells occupy a volume of 1 cm 3 ). We performed 100 simulations per metastatic rate q (q in [10 −10
, 10
]) to estimate the parameters of our model.
MBCP cohort analysis.
All patients for whom we analysed tumour tissue provided written informed consent for research biopsies and transcriptome sequencing of tumour RNA, as approved by the DF/HCC IRB (protocol no. 05-246), before any study procedures were performed. The study is compliant with all of the relevant ethical regulations regarding research involving human participants. The cohort consists of 51 primary tumours (formalin-fixed paraffin-embedded samples) and matching 155 metastatic lesions (mostly frozen tissue) enriched in ER + subtype. Because of the difference in tissue-preservation methods between primary and metastatic lesions, batch effects cannot be ruled out when comparing primary and metastatic lesions 45 . Total RNA was extracted using a RNeasy mini kit (Qiagen) and libraries for RNA-seq were prepared using the TrueSeq RNA sample preparation kit protocol adapted for the Sciclone liquid handler (PerkinElmer). Sequencing was performed on an Illumina Nextseq500. Reads were aligned to the hg19 human genome using STAR v.2.5.1 (ref. 46 ) followed by Transcript assembly using cufflinks v.2.2.1 (ref. 47 ). Quality-control steps were done using STAR v.2.5.1 and RseQC v.2.6.2 (ref. 48 ). We assessed each sample on metrics of mappable reads, percentage of rRNA reads, gene body coverage, and junction saturation and insert_size for paired ends to determine which samples were of adequate quality. Signatures of IL11/FIGF-activated neutrophils and MSCs from blood and lungs were derived from differentially expressed gene lists from our scRNA-seq analysis. We aimed to construct the signatures using the top 150 differentially expressed genes, unless fewer genes presented with an adjusted P < 0.05. The signature of the cancer cells was derived from the top 150 genes that were differentially expressed between the Thy1.1 neutral clone sorted from polyclonal tumour and the parental cell line tumour. All signatures are presented in Supplementary Table 6 . Signature analysis on the MBCP and TCGA data was performed using GSVA 49 .
Statistics and reproducibility. The sample sizes for the mouse experiments were determined based on previous studies and pilot experiments to ensure that sufficient power could be obtained 7 . Unless otherwise stated, statistical analyses were performed using GraphPad Prism software or R. Box-and-whisker plots show the mean (midline), and 25th-75th (box) and 5th-95th percentiles (whiskers). Most experiments in this study were performed independently at least twice and nature research | reporting summary 
Field-collected samples
Study did not involve field-collected samples.
Ethics oversight
All animal procedures were approved by DFCI ACUC and performed according to DFCI protocol #11-023. All patients participating in the MBC Project provided a written informed consent for research metastatic biopsies and genomic profiling of tumor RNA. The study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DF/HCC Protocol 05-246).
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation FACS analysis was performed on blood, primary tumors and metastatic lungs. Blood samples were collected by retroorbital bleeding or cardiac puncture, subject to erythrolysis and stained according to standard protocols. Lung and tumor samples were digested into single cell suspension with collagenase/hyaluronidase/DNase mix, washed and stained accordingly. Cell population abundance CD45 cell sorting was previously validated in the lab by RNAseq of known positive and negative cell populations. IL11RA and PLXDC2 cell sorting were validated by flow cytometic analysis and correlation to RNAseq data from cell lines with and without expression of these proteins.
Gating strategy FSC/SSC gates were chosen to eliminate debris and doublets. For cell sorting experiment for single-cell RNAseq , dead cells were eliminated by excluding 7AAD+ cells. For cell sorting experiment for bulk RNAseq , live cells were gated based on FSC and SSC. Within a single experiment, gating was chosen based on random sample gating, before a single gate was applied to all plots for final analysis. An example of gating strategy is presented in the Supplementary Fig. 1, 3 , and 6.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
